Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + tomivosertib
- Development stage
- Discontinued
- Lead developer
- Effector Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + tomivosertib is a combination therapy investigated for the treatment of non-small cell lung cancer (NSCLC). Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells and acts as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Tomivosertib is a selective small molecule inhibitor of MAP kinase-interacting serine/threonine-protein kinase 1 and 2 (MNK1/2), which are involved in regulating mRNA translation in cancer cells. The combination was studied as frontline therapy for NSCLC patients with high PD-L1 expression but did not demonstrate sufficient efficacy to warrant further development in this indication[1][3][5][9].
- Brand names
- Keytruda
- Other names
- pembrolizumab + tomivosertibMK-3475 + eFT508
02
Targets
MKNK1 (Mitogen‑activated protein kinase‑interacting serine/threonine-protein kinase 1)MKNK2 (MAP kinase-interacting serine/threonine-protein kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + tomivosertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + tomivosertib.